Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: UTR024
MIFTS: 60

Uterine Carcinosarcoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Uterine Carcinosarcoma

About this section

MalaCards integrated aliases for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma 12 53 59 55 6 15 73
Malignant Mixed Müllerian Tumor of the Corpus Uteri 53 59
Mixed Müllerian Cancer of Corpus Uteri 53 59
Carcinosarcoma of the Corpus Uteri 53 59
Malignant Mixed Müllerian Tumor of Corpus Uteri 53
Mixed Mullerian Sarcoma of Uterus 12
Uterine Corpus Carcinosarcoma 73

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:6171
NCIt 50 C42700
Orphanet 59 ORPHA213610
ICD10 via Orphanet 34 C54.9
Sources

Summaries for Uterine Carcinosarcoma

About this section
NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 213610Disease definitionCarcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported.Visit the Orphanet disease page for more resources.

MalaCards based summary : Uterine Carcinosarcoma, also known as malignant mixed müllerian tumor of the corpus uteri, is related to carcinosarcoma and leiomyosarcoma, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, lung and lymph node, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

Sources

Related Diseases for Uterine Carcinosarcoma

About this section

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 31.2 CTNNB1 ERBB2 HRAS KIT MME PGR
2 leiomyosarcoma 30.7 KIT PGR TP53
3 sarcoma 30.7 CTNNB1 HRAS KIT PIK3CA TP53
4 endometrial stromal sarcoma 30.3 KIT MME PGR TP53
5 fallopian tube carcinoma 30.2 ERBB2 PGR TP53
6 cervical squamous cell carcinoma 30.1 CDH1 CTNNB1 TP53
7 wilms tumor 1 30.0 CTNNB1 ERBB2 FBXW7 PGR TP53
8 chordoma 30.0 CDH1 EGFR PTEN
9 adenosarcoma 30.0 KIT MME PGR TP53
10 cervical cancer 29.5 CDH1 CTNNB1 ERBB2 HRAS PIK3CA PTEN
11 squamous cell carcinoma 29.1 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
12 adenocarcinoma 29.0 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
13 colorectal cancer 29.0 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
14 breast cancer 28.6 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
15 endometrial cancer 28.3 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
16 malignant spiradenoma 10.4 PIK3CA TP53
17 rare adenocarcinoma of the breast 10.4 PIK3CA TP53
18 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
19 thyroid hurthle cell adenoma 10.4 PIK3CA PTEN
20 apocrine adenoma 10.4 HRAS PIK3CA
21 prostate adenoid cystic carcinoma 10.4 HRAS PIK3CA
22 prostate transitional cell carcinoma 10.4 CTNNB1 PIK3CA
23 intracystic papillary adenoma 10.4 ERBB2 PGR
24 thymoma, familial 10.4 HRAS KIT
25 breast metaplastic carcinoma 10.4 ERBB2 PGR
26 breast medullary carcinoma 10.4 ERBB2 PGR
27 breast apocrine carcinoma 10.4 ERBB2 PGR
28 glassy cell carcinoma of the cervix 10.4 ERBB2 PGR
29 bent bone dysplasia syndrome 10.4 ERBB2 FGFR2
30 immunodeficiency 14 10.4 PIK3R1 PTEN
31 protoplasmic astrocytoma 10.3 PTGS2 TP53
32 brain ependymoma 10.3 EGFR TP53
33 breast intraductal proliferative lesion 10.3 EGFR ERBB2
34 female breast cancer 10.3 ERBB2 PGR TP53
35 peutz-jeghers syndrome 10.3 CTNNB1 PTEN TP53
36 sweat gland cancer 10.3 ERBB2 PGR TP53
37 cell type benign neoplasm 10.3 CTNNB1 HRAS TP53
38 muscle cancer 10.3 KIT PGR TP53
39 anal squamous cell carcinoma 10.3 FBXW7 PIK3CA TP53
40 adult hepatocellular carcinoma 10.3 CTNNB1 PIK3CA TP53
41 li-fraumeni syndrome 10.3 EGFR PTEN TP53
42 brain stem glioma 10.3 EGFR PIK3CA TP53
43 supratentorial cancer 10.3 EGFR PTEN TP53
44 giant cell glioblastoma 10.3 EGFR PTEN TP53
45 grade iii astrocytoma 10.3 EGFR PTEN TP53
46 nervous system cancer 10.3 EGFR PTEN TP53
47 central nervous system cancer 10.3 EGFR PTEN TP53
48 cerebrum cancer 10.3 EGFR PTEN TP53
49 cutis marmorata telangiectatica congenita 10.3 PIK3CA PIK3R2
50 megalencephaly-capillary malformation-polymicrogyria syndrome 10.3 PIK3CA PIK3R2

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:



Diseases related to Uterine Carcinosarcoma
Sources

Symptoms & Phenotypes for Uterine Carcinosarcoma

About this section

UMLS symptoms related to Uterine Carcinosarcoma:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

26 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.73 EGFR HRAS PIK3CA
2 Decreased viability GR00173-A 10.73 PIK3R2
3 Decreased viability GR00221-A-1 10.73 CDH1 KIT PIK3R2 EGFR HRAS PIK3CA
4 Decreased viability GR00221-A-2 10.73 PIK3R2 HRAS PIK3CA
5 Decreased viability GR00221-A-3 10.73 HRAS PIK3R1
6 Decreased viability GR00221-A-4 10.73 PIK3R2 EGFR PIK3CA
7 Decreased viability GR00301-A 10.73 CDH1 FGFR2 KIT PIK3R2
8 Decreased viability GR00342-S-1 10.73 FGFR2
9 Decreased viability GR00342-S-2 10.73 FGFR2
10 Decreased viability GR00342-S-3 10.73 FGFR2
11 Decreased viability GR00402-S-2 10.73 CDH1 FGFR2 KIT PIK3R2 EGFR HRAS
12 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.36 PIK3R1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.36 PIK3R1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.36 EGFR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.36 EGFR FBXW7
16 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.36 FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.36 FBXW7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.36 FBXW7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.36 SOX4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.36 FBXW7 PIK3R1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.36 FBXW7 HRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.36 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.36 SOX4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.36 HRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.36 SOX4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.36 PIK3R1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.36 EGFR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.36 EGFR PIK3R1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.36 EGFR FBXW7 HRAS PIK3R1 SOX4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.36 FBXW7
31 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.36 SOX4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.36 SOX4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.36 HRAS
34 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.36 EGFR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.36 PIK3R1
36 Decreased viability in esophageal squamous lineage GR00235-A 10.02 CDH1 CTNNB1 ERBB2 HRAS KIT PGR
37 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.95 CTNNB1 EGFR ERBB2 FGFR2 HRAS PPP2R1A
38 Increased cell death HMECs cells GR00103-A-0 9.86 CTNNB1 EGFR FBXW7 PGR PIK3CA PPP2R1A
39 Decreased cell migration GR00055-A-1 9.83 CTNNB1 EGFR HRAS PIK3CA PIK3R2
40 Increased transferrin (TF) endocytosis GR00363-A 9.8 EGFR ERBB2 ESR2 FBXW7 HRAS KIT
41 Reduced mammosphere formation GR00396-S 9.17 CDH1 EGFR HRAS PIK3R1 PPP2R1A PTEN

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.58 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
2 homeostasis/metabolism MP:0005376 10.57 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
3 growth/size/body region MP:0005378 10.55 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
4 cellular MP:0005384 10.5 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
5 endocrine/exocrine gland MP:0005379 10.5 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
6 behavior/neurological MP:0005386 10.48 CTNNB1 ERBB2 ESR2 FGFR2 HRAS KIT
7 integument MP:0010771 10.48 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
8 digestive/alimentary MP:0005381 10.46 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
9 immune system MP:0005387 10.46 CDH1 CTNNB1 EGFR ESR2 FBXW7 FGFR2
10 mortality/aging MP:0010768 10.46 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
11 embryo MP:0005380 10.45 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
12 neoplasm MP:0002006 10.41 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
13 hematopoietic system MP:0005397 10.39 CTNNB1 EGFR ESR2 FBXW7 FGFR2 KIT
14 craniofacial MP:0005382 10.32 CTNNB1 EGFR ERBB2 FBXW7 FGFR2 HRAS
15 muscle MP:0005369 10.31 CTNNB1 EGFR ERBB2 ESR2 FGFR2 KIT
16 normal MP:0002873 10.31 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
17 nervous system MP:0003631 10.3 CTNNB1 EGFR ERBB2 ESR2 FBXW7 FGFR2
18 liver/biliary system MP:0005370 10.26 CTNNB1 EGFR ESR2 FBXW7 FGFR2 KIT
19 adipose tissue MP:0005375 10.24 EGFR ESR2 FGFR2 PIK3CA PIK3R1 PTEN
20 limbs/digits/tail MP:0005371 10.24 CTNNB1 EGFR ERBB2 ESR2 FGFR2 KIT
21 no phenotypic analysis MP:0003012 10.17 CDH1 CTNNB1 EGFR ESR2 FGFR2 HRAS
22 reproductive system MP:0005389 10.07 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
23 hearing/vestibular/ear MP:0005377 10.06 CTNNB1 EGFR ESR2 FGFR2 KIT TP53
24 renal/urinary system MP:0005367 10.02 CTNNB1 EGFR ESR2 FGFR2 HRAS KIT
25 respiratory system MP:0005388 9.93 CTNNB1 EGFR ERBB2 ESR2 FBXW7 FGFR2
26 pigmentation MP:0001186 9.91 CTNNB1 EGFR FGFR2 KIT PTEN SNAI2
27 skeleton MP:0005390 9.8 CTNNB1 EGFR ERBB2 ESR2 FGFR2 HRAS
28 vision/eye MP:0005391 9.36 CTNNB1 EGFR FBXW7 FGFR2 KIT PIK3CA
Sources

Drugs & Therapeutics for Uterine Carcinosarcoma

About this section

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
5
Ifosfamide Approved Phase 3 3778-73-2 3690
6
Mesna Approved, Investigational Phase 3 3375-50-6 598
7
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
8
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
9
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11
Doxil Approved June 1999 Phase 3,Phase 2 31703
12 Alkylating Agents Phase 3,Phase 2
13 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
14 Antineoplastic Agents, Alkylating Phase 3,Phase 2
15 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
17
Isophosphamide mustard Phase 3 0
18 Anti-Bacterial Agents Phase 3,Phase 2
19 Topoisomerase Inhibitors Phase 3,Phase 2
20 Antibiotics, Antitubercular Phase 3,Phase 2
21 Serotonin Agents Phase 3
22 Anti-Allergic Agents Phase 3
23 Serotonin Antagonists Phase 3
24 Histamine H1 Antagonists Phase 3
25
Histamine Phosphate Phase 3 51-74-1 65513
26 Antipruritics Phase 3
27 Neurotransmitter Agents Phase 3
28 Dermatologic Agents Phase 3
29 Histamine Antagonists Phase 3
30 Gastrointestinal Agents Phase 3
31
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
32
Gemcitabine Approved Phase 2 95058-81-4 60750
33
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
34
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
35
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
36
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
37
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
40
Everolimus Approved Phase 2 159351-69-6 6442177
41
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
42
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
43
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
44
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
45
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
46
Metformin Approved Phase 2 657-24-9 14219 4091
47
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
48
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Iniparib Investigational Phase 2 160003-66-7

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
3 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
4 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
5 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
6 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
9 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
10 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
11 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
12 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
13 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
14 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
15 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
16 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
17 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
18 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
19 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
20 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
21 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
22 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
23 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
24 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
25 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
26 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
27 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
28 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
29 Vorinostat (SAHA) in Uterine Sarcoma Recruiting NCT03509207 Phase 2 Vorinostat Oral Capsule
30 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
31 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
32 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2 Trabectedin
33 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
34 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
35 Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus Terminated NCT00003156 Phase 2 topotecan hydrochloride
36 Suitability of DCE-MRI for Detection of Vascular Changes After VBT Unknown status NCT01991808 Phase 1
37 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
38 Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting NCT03552471 Phase 1 Rucaparib Camsylate
39 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
40 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer Unknown status NCT01367301 Not Applicable paclitaxel;carboplatin
41 Lymph Node Counts in Endometrial Cancer Staging Completed NCT02335775

Search NIH Clinical Center for Uterine Carcinosarcoma

Sources

Genetic Tests for Uterine Carcinosarcoma

About this section
Sources

Anatomical Context for Uterine Carcinosarcoma

About this section

MalaCards organs/tissues related to Uterine Carcinosarcoma:

41
Uterus, Lung, Lymph Node, Colon, Bone, Ovary, Thyroid
Sources

Publications for Uterine Carcinosarcoma

About this section

Articles related to Uterine Carcinosarcoma:

(show top 50) (show all 198)
# Title Authors Year
1
Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. ( 29791913 )
2018
2
Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. ( 29971677 )
2018
3
Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Evaluation of an Interesting Case of Uterine Carcinosarcoma with Isolated Appendicular Skeletal Metastases. ( 29643680 )
2018
4
Trends of uterine carcinosarcoma in the United States. ( 29400015 )
2018
5
Tumor Mutational Burden Guides Therapy in a Treatment Refractory<i>POLE-</i>Mutant Uterine Carcinosarcoma. ( 29386312 )
2018
6
The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma. ( 29629727 )
2018
7
Diagnostic accuracy of 3.0T diffusion-weighted MRI for patients with uterine carcinosarcoma: Assessment of tumor extent and lymphatic metastasis. ( 29437265 )
2018
8
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. ( 29455465 )
2018
9
Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. ( 29303931 )
2018
10
Significance of venous thromboembolism in women with uterine carcinosarcoma. ( 29248197 )
2018
11
Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis. ( 29097136 )
2018
12
Radiation-Induced Uterine Carcinosarcoma after Concurrent Chemoradiotherapy for Cervical Squamous Cell Carcinoma. ( 30308682 )
2018
13
Uterine carcinosarcoma (malignant mixed Müllerian tumor): case report in a goat and literature review. ( 30345891 )
2018
14
Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework. ( 30359167 )
2018
15
Prognostic factors impacting survival in early stage uterine carcinosarcoma. ( 30414738 )
2018
16
Ultrasonographic Findings of Uterine Carcinosarcoma. ( 30504724 )
2018
17
Diagnostic Value of 18F-FDG PET/CT and MRI in the Preoperative Evaluation of Uterine Carcinosarcoma. ( 30538776 )
2018
18
Uterine Carcinosarcoma with Alpha-Fetoprotein-Producing Hepatoid Component: A Case Report and Literature Review. ( 29992073 )
2018
19
A Case of Uterine Carcinosarcoma Detected Simultaneously with Breast and Colon Cancer (Triple Primary Malignant Tumor). ( 30057538 )
2018
20
Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. ( 30105438 )
2018
21
L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition. ( 30140948 )
2018
22
Clinical utility of CA-125 in the management of uterine carcinosarcoma. ( 30207096 )
2018
23
Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. ( 30217299 )
2018
24
Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. ( 29056442 )
2017
25
Identification of distinct molecular subtypes of uterine carcinosarcoma. ( 28178664 )
2017
26
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. ( 28317560 )
2017
27
Prognostic value of metabolic parameters determined by preoperative A^a8,F-FDG PET/CT in patients with uterine carcinosarcoma. ( 28541634 )
2017
28
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. ( 28930812 )
2017
29
Port-Site Metastasis of Uterine Carcinosarcoma after Laparoscopy. ( 28960047 )
2017
30
Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma. ( 28836024 )
2017
31
Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report. ( 28424084 )
2017
32
Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis. ( 28574930 )
2017
33
Integrated Molecular Characterization of Uterine Carcinosarcoma. ( 28292439 )
2017
34
Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. ( 29044542 )
2017
35
Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival. ( 28121642 )
2017
36
Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. ( 27931750 )
2017
37
Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. ( 28088687 )
2017
38
Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. ( 28657223 )
2017
39
Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma. ( 28704324 )
2017
40
Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports. ( 28761924 )
2017
41
Patterns of Adjuvant Therapy Utilization in Uterine Carcinosarcoma Stages I to III: A National Cancer Database Analysis. ( 28654573 )
2017
42
Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma. ( 28193280 )
2017
43
A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus. ( 28584958 )
2017
44
Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. ( 28318642 )
2017
45
Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. ( 28215838 )
2017
46
Comprehensive Staging of Uterine Carcinosarcoma Using a Multiquadrant Robotic Platform. ( 27794476 )
2017
47
Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS. ( 27889902 )
2017
48
Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. ( 27009459 )
2016
49
Adjuvant radiation therapy in uterine carcinosarcoma: A population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. ( 26896827 )
2016
50
Uterine carcinosarcoma including angiosarcoma: A short case report. ( 27592347 )
2016
Sources

Variations for Uterine Carcinosarcoma

About this section

ClinVar genetic disease variations for Uterine Carcinosarcoma:

6 (show top 50) (show all 350)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
7 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
8 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
9 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
10 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
13 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
14 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
20 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
21 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
22 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
23 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
24 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
25 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
26 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
27 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
28 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
29 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
31 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
32 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
33 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
34 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
35 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
36 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
37 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
38 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
39 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
40 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
41 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
42 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
43 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
44 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
45 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
46 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
47 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
48 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
49 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
50 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
Sources

Expression for Uterine Carcinosarcoma

About this section
Search GEO for disease gene expression data for Uterine Carcinosarcoma.
Sources

Pathways for Uterine Carcinosarcoma

About this section

Pathways related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 66
Show member pathways
 14.33 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
2
Innate Immune System 66
Show member pathways
 14.18 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
3
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 14.01 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
4
ERK Signaling 64
Show member pathways
 13.98 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
5
GPCR Pathway 64
Show member pathways
 13.89 EGFR ERBB2 ESR2 FGFR2 HRAS KIT
6
HIV Life Cycle 66
Show member pathways
 13.89 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
7
PEDF Induced Signaling 64
Show member pathways
 13.84 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
8
TGF-Beta Pathway 64
Show member pathways
 13.72 CDH1 EGFR ERBB2 FGFR2 HRAS KIT
9
Activation of cAMP-Dependent PKA 64
Show member pathways
 13.69 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
10
Developmental Biology 66
Show member pathways
 13.68 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
11
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.61 CDH1 EGFR ERBB2 FBXW7 FGFR2 HRAS
12
Akt Signaling 64
Show member pathways
 13.59 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
13
Cytokine Signaling in Immune system 66
Show member pathways
 13.55 EGFR ERBB2 FGFR2 HRAS KIT PIK3CA
14
CREB Pathway 64
Show member pathways
 13.49 EGFR ERBB2 FGFR2 HRAS KIT PIK3R1
15
PAK Pathway 64
Show member pathways
 13.48 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
16
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.46 CDH1 CTNNB1 EGFR ERBB2 ESR2 FGFR2
17
IL-2 Pathway 64
Show member pathways
 13.36 EGFR ERBB2 HRAS PIK3R1 PIK3R2 PTEN
18
PI3K/AKT activation 66
Show member pathways
 13.32 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
19
Phospholipase-C Pathway 64
Show member pathways
 13.26 EGFR FGFR2 HRAS KIT PIK3R1 PIK3R2
20
Human cytomegalovirus infection 37
Show member pathways
 13.25 CTNNB1 EGFR HRAS PIK3CA PIK3R1 PIK3R2
21
p70S6K Signaling 64
Show member pathways
 13.24 EGFR FGFR2 HRAS KIT PIK3R1 PIK3R2
22
DAG and IP3 signaling 66
Show member pathways
 13.23 EGFR HRAS PIK3R1 PIK3R2 PPP2R1A PTGS2
23
Circadian entrainment 37
Show member pathways
 13.23 EGFR ESR2 HRAS PGR PIK3CA PIK3R1
24
G-Beta Gamma Signaling 64
Show member pathways
 13.18 CTNNB1 EGFR HRAS PIK3R1 PIK3R2 PTGS2
25
fMLP Pathway 64
Show member pathways
 13.16 CDH1 CTNNB1 HRAS PIK3R1 PIK3R2 TP53
26
TNFR1 Pathway 64
Show member pathways
 13.15 CTNNB1 EGFR HRAS PIK3CA PIK3R1 PIK3R2
27
Actin Nucleation by ARP-WASP Complex 64
Show member pathways
 13.14 CDH1 EGFR ERBB2 FGFR2 HRAS KIT
28
Sertoli-Sertoli Cell Junction Dynamics 64
Show member pathways
 13.11 CDH1 CTNNB1 HRAS PIK3R1 PIK3R2 PPP2R1A
29
Development Angiotensin activation of ERK 22
Show member pathways
 13.1 EGFR HRAS KIT PIK3CA PIK3R1 PIK3R2
30
Focal Adhesion 1 37
Show member pathways
 13.1 CTNNB1 EGFR ERBB2 HRAS PIK3CA PIK3R1
31
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.09 EGFR ERBB2 HRAS PIK3CA PIK3R1 PIK3R2
32
NFAT and Cardiac Hypertrophy 64
Show member pathways
 13.07 EGFR ERBB2 FGFR2 HRAS PIK3CA PIK3R1
33
MAPK-Erk Pathway 67
Show member pathways
 12.95 ESR2 HRAS PIK3CA PIK3R1 PIK3R2
34
Apoptosis Modulation and Signaling 1
Show member pathways
 12.94 HRAS PIK3CA PIK3R1 PIK3R2 TP53
35
MAPK signaling pathway 37 1
12.94 EGFR ERBB2 FGFR2 HRAS KIT TP53
36
Beta-Adrenergic Signaling 64
Show member pathways
 12.93 CTNNB1 HRAS PIK3R1 PIK3R2 PPP2R1A
37
Ras signaling pathway 37
Show member pathways
 12.93 CDH1 CTNNB1 EGFR FGFR2 HRAS KIT
38
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.91 HRAS PIK3CA PIK3R1 PIK3R2 PTEN
39
PI3K-Akt signaling pathway 37
Show member pathways
 12.91 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
40
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.87 CTNNB1 EGFR HRAS PIK3CA PIK3R1 PIK3R2
41
Development HGF signaling pathway 22
Show member pathways
 12.87 CDH1 CTNNB1 ERBB2 HRAS PIK3CA PIK3R1
42
4-1BB Pathway 64
Show member pathways
 12.86 EGFR HRAS PIK3R1 PIK3R2 PPP2R1A TP53
43
Cell junction organization 66
Show member pathways
 12.85 CDH1 CTNNB1 PIK3CA PIK3R1 PIK3R2
44
Glioma 37
Show member pathways
 12.84 CDH1 EGFR ERBB2 ESR2 FGFR2 HRAS
45
Endometrial cancer 37
Show member pathways
 12.84 CDH1 CTNNB1 EGFR ERBB2 FGFR2 HRAS
46
Regulation of actin cytoskeleton 1 37
12.82 EGFR FGFR2 HRAS PIK3CA PIK3R1 PIK3R2
47
Immune response IL-23 signaling pathway 22
Show member pathways
 12.8 CTNNB1 EGFR ERBB2 HRAS PIK3CA PIK3R1
48
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.78 HRAS PIK3CA PIK3R1 PIK3R2 PTEN PTGS2
49
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.77 EGFR HRAS PIK3CA PIK3R1 PIK3R2 PPP2R1A
50
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.75 EGFR ERBB2 FGFR2 HRAS KIT PIK3CA
Sources

GO Terms for Uterine Carcinosarcoma

About this section

Cellular components related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.8 CDH1 CTNNB1 EGFR ERBB2 FBXW7 HRAS
2 receptor complex GO:0043235 9.73 EGFR ERBB2 FGFR2 KIT
3 lateral plasma membrane GO:0016328 9.58 CDH1 CTNNB1 PPP2R1A
4 cytoplasm GO:0005737 9.58 CDH1 CTNNB1 EGFR ERBB2 FBXW7 FGFR2
5 cytoplasmic side of plasma membrane GO:0009898 9.54 CDH1 KIT PTEN
6 flotillin complex GO:0016600 9.46 CDH1 CTNNB1
7 phosphatidylinositol 3-kinase complex, class IA GO:0005943 9.16 PIK3CA PIK3R1
8 phosphatidylinositol 3-kinase complex GO:0005942 9.13 PIK3CA PIK3R1 PIK3R2
9 nucleus GO:0005634 10.13 CTNNB1 EGFR ERBB2 ESR2 FBXW7 FGFR2

Biological processes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.99 CTNNB1 EGFR KIT PTGS2
2 protein autophosphorylation GO:0046777 9.99 EGFR ERBB2 FGFR2 KIT
3 protein stabilization GO:0050821 9.99 FBXW7 PIK3R1 PTEN SOX4
4 positive regulation of cell migration GO:0030335 9.98 EGFR HRAS KIT PIK3R1 SNAI2
5 MAPK cascade GO:0000165 9.97 EGFR ERBB2 FGFR2 HRAS KIT
6 positive regulation of cell proliferation GO:0008284 9.97 CTNNB1 EGFR FGFR2 HRAS KIT PTEN
7 T cell receptor signaling pathway GO:0050852 9.94 HRAS PIK3CA PIK3R1 PIK3R2
8 negative regulation of signal transduction GO:0009968 9.93 EGFR ERBB2 FGFR2 KIT
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 CTNNB1 ESR2 KIT PTEN
10 response to estradiol GO:0032355 9.91 CTNNB1 EGFR PTEN PTGS2
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.9 EGFR PIK3CA PTGS2
12 lung development GO:0030324 9.9 CTNNB1 EGFR FBXW7 FGFR2
13 response to organic substance GO:0010033 9.89 CDH1 PPP2R1A PTEN PTGS2
14 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.88 PIK3CA PIK3R1 PIK3R2
15 cellular response to growth factor stimulus GO:0071363 9.88 CTNNB1 EGFR ERBB2
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.88 EGFR FGFR2 PTGS2
17 epidermal growth factor receptor signaling pathway GO:0007173 9.87 EGFR PIK3CA PIK3R1
18 cellular response to UV GO:0034644 9.86 PIK3R1 PTGS2 TP53
19 cellular response to epidermal growth factor stimulus GO:0071364 9.85 EGFR ERBB2 SNAI2
20 phosphatidylinositol-mediated signaling GO:0048015 9.84 PIK3CA PIK3R1 PIK3R2
21 T cell differentiation GO:0030217 9.83 CTNNB1 KIT SOX4
22 epithelial to mesenchymal transition GO:0001837 9.83 CTNNB1 FGFR2 SNAI2
23 positive regulation of epithelial cell proliferation GO:0050679 9.83 EGFR ERBB2 FGFR2 HRAS
24 response to radiation GO:0009314 9.82 KIT PTGS2 SNAI2
25 positive regulation of MAP kinase activity GO:0043406 9.81 EGFR ERBB2 HRAS KIT
26 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.8 FGFR2 PIK3CA PIK3R1 PIK3R2
27 positive regulation of MAPK cascade GO:0043410 9.8 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
28 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 EGFR ERBB2 FBXW7 FGFR2 HRAS KIT
29 regulation of ERK1 and ERK2 cascade GO:0070372 9.79 EGFR ERBB2 FGFR2
30 vasculature development GO:0001944 9.78 CTNNB1 FBXW7 PIK3CA
31 phosphatidylinositol 3-kinase signaling GO:0014065 9.76 ERBB2 PIK3CA PIK3R1 PIK3R2
32 positive regulation of protein import into nucleus GO:0042307 9.73 CDH1 PIK3R1 PIK3R2 PTGS2
33 morphogenesis of embryonic epithelium GO:0016331 9.72 CTNNB1 FGFR2
34 tongue development GO:0043586 9.72 EGFR KIT
35 limb bud formation GO:0060174 9.72 FGFR2 SOX4
36 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.71 EGFR TP53
37 entry of bacterium into host cell GO:0035635 9.71 CDH1 CTNNB1
38 lung-associated mesenchyme development GO:0060484 9.71 CTNNB1 FGFR2
39 regulation of osteoblast differentiation GO:0045667 9.71 CTNNB1 FGFR2 SNAI2
40 ERBB2 signaling pathway GO:0038128 9.71 EGFR ERBB2 PIK3CA PIK3R1
41 negative regulation of ERBB signaling pathway GO:1901185 9.7 EGFR ERBB2
42 positive regulation of protein kinase B signaling GO:0051897 9.7 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
43 cellular response to indole-3-methanol GO:0071681 9.68 CDH1 CTNNB1
44 negative regulation of apoptotic process GO:0043066 9.65 CTNNB1 EGFR ERBB2 FGFR2 KIT PIK3R1
45 mesenchymal cell proliferation involved in lung development GO:0060916 9.64 CTNNB1 FGFR2
46 phosphatidylinositol phosphorylation GO:0046854 9.17 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
47 signal transduction GO:0007165 10.33 EGFR ERBB2 ESR2 HRAS KIT PGR
48 cell differentiation GO:0030154 10.2 CTNNB1 EGFR ERBB2 FGFR2 KIT SOX4
49 protein phosphorylation GO:0006468 10.16 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
50 positive regulation of transcription, DNA-templated GO:0045893 10.14 CDH1 CTNNB1 EGFR ESR2 SOX4 TP53

Molecular functions related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.91 EGFR ERBB2 FGFR2 HRAS KIT
2 enzyme binding GO:0019899 9.87 CTNNB1 EGFR ESR2 PGR PTEN PTGS2
3 protein heterodimerization activity GO:0046982 9.86 CTNNB1 EGFR ERBB2 PIK3R1 PIK3R2 PPP2R1A
4 transmembrane signaling receptor activity GO:0004888 9.84 EGFR ERBB2 FGFR2 KIT
5 protein tyrosine kinase activity GO:0004713 9.8 EGFR ERBB2 FGFR2 KIT
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.76 EGFR ERBB2 FGFR2 KIT
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.71 EGFR ERBB2 FGFR2 KIT
8 1-phosphatidylinositol-3-kinase activity GO:0016303 9.67 FGFR2 PIK3CA PIK3R1 PIK3R2
9 insulin receptor substrate binding GO:0043560 9.55 PIK3CA PIK3R1
10 phosphatidylinositol 3-kinase regulator activity GO:0035014 9.52 PIK3R1 PIK3R2
11 ErbB-3 class receptor binding GO:0043125 9.48 ERBB2 PIK3R1
12 protein phosphatase binding GO:0019903 9.43 CTNNB1 EGFR ERBB2 PIK3R1 PIK3R2 TP53
13 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.17 EGFR ERBB2 FGFR2 KIT PIK3CA PIK3R1
14 protein binding GO:0005515 10.16 CDH1 CTNNB1 EGFR ERBB2 ESR2 FBXW7
15 identical protein binding GO:0042802 10.03 CDH1 EGFR ERBB2 ESR2 FBXW7 PGR
Sources

Sources for Uterine Carcinosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....